Would you recommend imatinib 400 mg BID or stay with the usual dose of 400 mg/day for adjuvant therapy for a patient with intermediate-high risk exon 9 mutated GIST?  

This is an issue that has been debated for more than 10 years with no clear-cut evidence-based answer. A case can be made for both options. I personally start with 400 mg/d, watch the disease closely, and the first indication that the benefit is in question, increase the dose to 800 mg/d. Tolerance ...